Brexpiprazole has a low risk of dopamine D2 receptor sensitization and inhibits rebound phenomena related to D2 and serotonin 5‐HT2A receptors in rats

• Principais autores: Naoki Amada (Autor), Hitomi Akazawa (Autor), Yuta Ohgi (Autor), Kenji Maeda (Autor), Haruhiko Sugino (Autor), Nobuyuki Kurahashi (Autor), Tetsuro Kikuchi (Autor), Takashi Futamura (Autor)
• Formato: Livro
• Publicado em: Wiley, 2019-12-01T00:00:00Z.
• Assuntos: article
• Acesso em linha: Connect to this object online.

Abstract Background Long‐term antipsychotic treatment in patients with schizophrenia can induce supersensitivity psychosis and tardive dyskinesia which is thought to be caused by dopamine D2 receptor sensitization. We evaluated the effects of brexpiprazole on D2 receptor sensitivity after subchronic...